Search results
Showing 1156 to 1170 of 1339 results for 0
Evidence-based recommendations on percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall.
View recommendations for IPG371Show all sections
Sections for IPG371
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for IPG380Show all sections
Sections for IPG380
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.
View quality statements for QS149Show all sections
Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
Guide to the processes of technology appraisal
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.
NICE has developed a medtech innovation briefing (MIB) on Biopatch for venous or arterial catheter sites .
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .
Mersey Burns for calculating fluid resuscitation volume when managing burns (MIB58)
NICE has developed a medtech innovation briefing (MIB) on Mersey Burns for calculating fluid resuscitation volume when managing burns
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system